PDF
Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers
Gavin P. Dowling, Gordon R. Daly, Aisling Hegarty, Michael Flanagan, Mihaela Ola, Ramón Fallon, Sinéad Cocchiglia, Vikrant Singh, Katherine M. Sheehan, Fiona Bane, Jason McGrath, Louise Watson, Sandra Hembrecht, Bryan Hennessy, Patrick G. Morris, Arnold D. K. Hill, Damir Varešlija, Leonie S. Young
Cancer Communications ›› 2025, Vol. 45 ›› Issue (02) : 198-202.
PDF
Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers
| [1] |
Uzun M, Atag E, Caliskan Yildirim E, Keser M, Semiz HS, Unal OU. Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy? Sci Rep. 2024; 14(1): 14651.
CrossRef
Google scholar
|
| [2] |
Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F. et al. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer. 2021; 7(1): 41.
CrossRef
Google scholar
|
| [3] |
Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O’Halloran PJ, et al. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst. 2019; 111(4): 388-98.
|
| [4] |
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375(9712): 377-84.
CrossRef
Google scholar
|
| [5] |
Zhao M, Kim P, Mitra R, Zhao J, Zhao Z. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 2016; 44(D1): D1023-31.
CrossRef
Google scholar
|
| [6] |
Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, et al. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015; 21(17): 3995-4003.
CrossRef
Google scholar
|
| [7] |
Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A. et al. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nat Commun. 2020; 11(1): 385.
CrossRef
Google scholar
|
| [8] |
Han Y, Wu Y, Xu H, Wang J, Xu B. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. International Journal of Clinical Oncology. 2022; 27(4): 707-16.
CrossRef
Google scholar
|
| [9] |
Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI. Sudhan DR, Nagy RJ, et al. Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clin Cancer Res. 2019; 25(1): 277-89.
CrossRef
Google scholar
|
| [10] |
Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positiv. Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol. 2021; 39(1): 79-89.
CrossRef
Google scholar
|
/
| 〈 |
|
〉 |
AI Summary
